|
Schizophrenia
|
0.310 |
Biomarker
|
disease |
BEFREE |
In addition, our data argues that increased levels of at least one miR, miR-107, is contributing to the marked loss of cortical CHRM1 in Def-Sz and this may be a differentiating pathophysiology.
|
23423139 |
2013 |
|
Schizophrenia
|
0.310 |
Biomarker
|
disease |
PSYGENET |
These observations were supported by quantitative reverse transcription-polymerase chain reaction, for miR-328, miR-17-5p, miR-134, miR-652, miR-382, and miR-107 and were consistent with a schizophrenia-associated increase in miRNA processing through elevated Dicer expression.
|
21111402 |
2011 |
|
Hepatitis, Toxic
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Drug-Induced Liver Disease
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Hepatitis, Drug-Induced
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Drug-Induced Acute Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Chemical and Drug Induced Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Chemically-Induced Liver Toxicity
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Hepatitis, Toxic
|
0.300 |
Biomarker
|
disease |
CTD_human |
Application of high-throughput sequencing to circulating microRNAs reveals novel biomarkers for drug-induced liver injury.
|
25359176 |
2015 |
|
Drug-Induced Liver Disease
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Application of high-throughput sequencing to circulating microRNAs reveals novel biomarkers for drug-induced liver injury.
|
25359176 |
2015 |
|
Hepatitis, Drug-Induced
|
0.300 |
Biomarker
|
disease |
CTD_human |
Application of high-throughput sequencing to circulating microRNAs reveals novel biomarkers for drug-induced liver injury.
|
25359176 |
2015 |
|
Drug-Induced Acute Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
Application of high-throughput sequencing to circulating microRNAs reveals novel biomarkers for drug-induced liver injury.
|
25359176 |
2015 |
|
Chemical and Drug Induced Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
Application of high-throughput sequencing to circulating microRNAs reveals novel biomarkers for drug-induced liver injury.
|
25359176 |
2015 |
|
Chemically-Induced Liver Toxicity
|
0.300 |
Biomarker
|
disease |
CTD_human |
Application of high-throughput sequencing to circulating microRNAs reveals novel biomarkers for drug-induced liver injury.
|
25359176 |
2015 |
|
Noise-induced hearing loss
|
0.300 |
Biomarker
|
disease |
CTD_human |
The miR-183/Taok1 target pair is implicated in cochlear responses to acoustic trauma.
|
23472202 |
2013 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The expression of miR-107 is down-regulated in AD patients and target genes of miR-107 have been shown to directly involved in AD.
|
31778666 |
2020 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
miR-103 may be a better choice than miR-107 to serve as a potential biomarker for disease risk and disease progression of AD.
|
31420923 |
2020 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
MicroRNA-107 inhibits proliferation and invasion of laryngeal squamous cell carcinoma cells by targeting CACNA2D1 in vitro.
|
31725046 |
2020 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to study the miR-107 in Alzheimer's Disease (AD) pathology through regulating SYK and NF-κB signaling pathway.
|
30543171 |
2019 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among the 121 miRNAs 22 were nominally significantly associated with CT and four of them (let-7g-5p, miR-103a-3p, miR-107, and miR-142-3p) also after correction for multiple testing; most of them were previously associated with Alzheimer's disease (AD) or depression.
|
31284290 |
2019 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
LncRNA NEAT1 aggravated Aβ-induced neuronal damage by sponging miR-107, indicating a novel avenue for treatment of AD.
|
31250578 |
2019 |
|
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Additionally, patients with the onset at 60-69 years of age showed a reduced level of miR-107 (p < 0.05, as compared to AD above 80 years of age).
|
31556571 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, miR-107 had anti-cancer potential by suppressing tumor initiation and progression in vivo.
|
30885433 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent studies have also demonstrated that microRNA-107 (miR-107) and tropomyosin alpha-1 (TPM1) are important regulators of cancer cell proliferation, but it remains unclear if these are involved in regulating the effect of Skullcapflavone I on CRC cells.
|
30509103 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Three genes (VCAM1, UBD, and RPA2), two miRNAs (miR-107 and miR-142-3p), and four pathways (p53, PI3K-Akt, autophagy, and transcription dysregulation in cancer) were identified to play critical roles in distinguishing HPV-positive OPSCC from HPV-negative OPSCC.
|
31036418 |
2019 |